125 related articles for article (PubMed ID: 33044045)
1. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
[TBL] [Abstract][Full Text] [Related]
3. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
[TBL] [Abstract][Full Text] [Related]
4. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).
Schmid S; Diem S; Li Q; Krapf M; Flatz L; Leschka S; Desbiolles L; Klingbiel D; Jochum W; Früh M
Cancer Immunol Immunother; 2018 Dec; 67(12):1825-1832. PubMed ID: 30171269
[TBL] [Abstract][Full Text] [Related]
5. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study.
Zhang G; Cheng R; Wang H; Zhang Y; Yan X; Li P; Zhang M; Zhang X; Yang J; Niu Y; Ma Z
Cancer Immunol Immunother; 2020 Mar; 69(3):399-405. PubMed ID: 31907567
[TBL] [Abstract][Full Text] [Related]
6. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.
Zhao B; Zhang W; Yu D; Xu J; Wei Y
Cancer Med; 2018 May; 7(5):1642-1659. PubMed ID: 29573217
[TBL] [Abstract][Full Text] [Related]
7. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab.
Ouaknine Krief J; Helly de Tauriers P; Dumenil C; Neveux N; Dumoulin J; Giraud V; Labrune S; Tisserand J; Julie C; Emile JF; Chinet T; Giroux Leprieur E
J Immunother Cancer; 2019 Jul; 7(1):176. PubMed ID: 31292005
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab.
Li P; Che G
Cancer Immunol Immunother; 2020 Mar; 69(3):489. PubMed ID: 31807877
[No Abstract] [Full Text] [Related]
9. Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer.
Menekse S; Kut E; Almuradova E
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):86-94. PubMed ID: 37869953
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of interstitial lung abnormalities and EGFR mutation status in patients with non-small cell lung cancer.
Xu X; Zhu M; Wang Z; Li J; Ouyang T; Chen C; Huang K; Zhang Y; Gao YL
Cancer Imaging; 2024 May; 24(1):66. PubMed ID: 38783331
[TBL] [Abstract][Full Text] [Related]
11. Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.
Bonaventura A; Grossi F; Carbone F; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Rossi G; Biello F; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
Cancer Immunol Immunother; 2019 Aug; 68(8):1351-1358. PubMed ID: 31327024
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.
Dusselier M; Deluche E; Delacourt N; Ballouhey J; Egenod T; Melloni B; Vergnenègre C; Veillon R; Vergnenègre A
PLoS One; 2019; 14(7):e0219060. PubMed ID: 31314761
[TBL] [Abstract][Full Text] [Related]
13. The relationship between clinicopathological variables, systemic inflammation, and CT-derived body composition with survival in patients with advanced non-small cell lung cancer receiving nivolumab as a second-line treatment.
Saeed R; McGovern J; Bench H; Dolan RD; McMillan DC; Cascales A
Cancer Med; 2023 Dec; 12(24):22062-22070. PubMed ID: 38088761
[TBL] [Abstract][Full Text] [Related]
14. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.
Naqash AR; Stroud CRG; Butt MU; Dy GK; Hegde A; Muzaffar M; Yang LV; Hafiz M; Cherry CR; Walker PR
Acta Oncol; 2018 Jun; 57(6):867-872. PubMed ID: 29241410
[No Abstract] [Full Text] [Related]
15. Air bronchogram on chest CT in radiological pure-solid appearance lung cancer: Correlation analysis with genetic pathological features and survival outcomes.
Wang Z; Zhu W; Yang M; Du H; Zhou F; Song N; Wan Z; Zhu J; Li W
Eur J Radiol; 2023 Dec; 169():111194. PubMed ID: 37976762
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ground-glass areas within tumours in non-small-cell lung cancer.
Sakurai H; Goto Y; Yoh K; Takamochi K; Shukuya T; Hishida T; Tsuboi M; Yoshida K; Ohde Y; Okumura S; Taguri M; Kunitoh H
Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38598462
[TBL] [Abstract][Full Text] [Related]
17. Automated CT quantification of interstitial lung abnormality in patients with resectable stage I non-small cell lung cancer: Prognostic significance.
Chung JH; Park JM; Kim DH
Thorac Cancer; 2024 Jun; 15(16):1305-1311. PubMed ID: 38682806
[TBL] [Abstract][Full Text] [Related]
18. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.
Ang YL; Lim JS; Soo RA
Onco Targets Ther; 2016; 9():3187-95. PubMed ID: 27313464
[TBL] [Abstract][Full Text] [Related]
19. Preoperative CT findings and prognosis of pulmonary sarcomatoid carcinoma: comparison with conventional NSCLC of similar tumor size.
Tang W; Wen C; Pei Y; Wu Z; Zhong J; Peng J; Zhong J
BMC Med Imaging; 2023 Aug; 23(1):105. PubMed ID: 37580691
[TBL] [Abstract][Full Text] [Related]
20. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Inoue Y; Inui N; Karayama M; Asada K; Fujii M; Matsuura S; Uto T; Hashimoto D; Matsui T; Ikeda M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Suda T
Cancer Immunol Immunother; 2023 Aug; 72(8):2717-2728. PubMed ID: 37099186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
